Business
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
BERLIN & BOSTON, January 08, 2026--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small interfering RNA (siRNA) therapy. The companies will collaborate to develop a siRNA-based treatment for a form of dilated cardiomyopathy, addressing a rare subset of heart disease.
About this update from Bayer Ag
[{"type":"text","content":"Not intended for UK Media","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy","length":118,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Bayer to further strengthen cardiovascular portfolio and enter dynamic field of siRNA by partnering with a leader in the field, Soufflé Therapeutics, to silence specific genes responsible for disease progression","length":211,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Soufflé leverages integrated proprietary technologies to engineer cell-selective siRNA therapy that targets cardiomyocytes to help address rare heart disease","length":157,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":486,"olType":false},{"type":"text","content":"BERLIN & BOSTON, January 08, 2026--(BUSINESS WIRE)--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small interfering RNA (siRNA) therapy. The companies will collaborate to develop a siRNA-based treatment for a form of dilated cardiomyopathy, addressing a rare subset of heart disease.","length":467,"tagName":"p"},{"type":"text","content":""We are excited to partner with Soufflé and begin exploring the field of siRNA, an innovative therapeutic modality that can potentially silence specific genes responsible for disease progression," said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals and Head of Leaps by Bayer. "This new collaboration allows us to expand our relationship with Soufflé, beyond our initial investment via Leaps by Bayer, the strategic investment unit of Bayer, further reinforcing our commitment to innovation and patients."","length":570,"tagName":"p"},{"type":"text","content":"Soufflé engineers cell-specific ligands to facilitate the precise delivery of siRNA-based medicines across cell membranes and directly in to target cells. By combining proprietary methods for identifying cell-specific receptors, optimizing ligands, and engineering potent siRNA, Soufflé aims to create safer, stronger, and more d...